Solely focusing on serum cytokines may be less clinically useful than originally posited, given that targeting individual cytokines associated with T2D pathogenesis, like IL-1β and TNF-α, did not improve insulin sensitivity or T2D onset in clinical trials [5,33,34]. Here, INS is linked to type 2 diabetes mellitus.